摘要免疫检查点抑制剂（ICI）的应用显著提高了不同类型恶性肿瘤的疗效，但其引起的免疫治疗相关不良事件（irAE）涉及多个器官和系统，影响治疗，威胁患者健康，甚至危及生命。因此，需要选择生物标志物来预测、监测irAE的发生，帮助高风险患者早期诊断，指导个体化治疗。研究表明，某些细胞因子参与了irAE的发生、发展。文章就细胞因子与irAE的相关研究进行综述，为临床预测和监测irAE提供参考。

abstractsThe use of immune checkpoint inhibitor (ICI) has significantly improved the efficacy of different types of malignancies, but the immune-related adverse event (irAE) callsed by ICI involves multiple organs and systems, affects the treatment, threatens the health of patients and even endangers their life. Therefore, it is necessary to select biomarkers to predict and monitor the occurrence of irAE, assist in the early diagnosis of high-risk patients, and guide individualized treatment. Recent studies have shown that some certain cytokines may be involved in the genesis and development of irAE. The article provides a review of studies related to cytokines and irAE to provide a reference for clinical prediction and monitoring of irAE.